Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pyxis Oncology, Inc. (PYXS) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, Pyxis Oncology uses its SEC reports to describe clinical progress, financial condition, governance matters, and material corporate events.
Investors can review Form 8-K filings that summarize significant developments such as preliminary Phase 1 data for micvotabart pelidotin (MICVO) in recurrent and metastatic head and neck squamous cell carcinoma, updates on ongoing monotherapy and combination studies, royalty and milestone transactions related to licensed antibodies, and key financial or corporate announcements. These current reports often incorporate or reference company press releases and presentations that detail MICVO’s clinical performance, safety profile, and translational findings.
In addition to 8-Ks, users can consult Pyxis Oncology’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more comprehensive discussions of research and development activities, cash resources and runway expectations, collaboration agreements, and risk factors relevant to its oncology programs. Proxy materials and meeting results, such as submissions under Item 5.07 for stockholder votes, provide insight into board composition and corporate governance.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify disclosures related to MICVO’s clinical trials, Fast Track Designation, collaboration with Merck on pembrolizumab combinations, and financial arrangements involving royalty streams from antibodies discovered on the APXiMAB platform. Real-time updates from EDGAR, along with structured access to forms such as 10-K, 10-Q, 8-K, and other relevant submissions, allow users to follow how Pyxis Oncology reports its oncology development and corporate trajectory over time.
Laurion Capital Management LP and related individuals report a significant ownership stake in Pyxis Oncology, Inc. They disclose beneficial ownership of 4,796,479 shares of Pyxis Oncology common stock, representing 7.72% of the class as of 12/31/2025.
Laurion Capital, along with Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, report shared voting and shared dispositive power over all of these shares and no sole power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pyxis Oncology.
Pyxis Oncology, Inc. announced a leadership transition in which Lara S. Sullivan, M.D. ceased serving as Chief Executive Officer and principal executive officer effective February 2, 2026. The Board appointed director Thomas (Tom) Civik as Interim Chief Executive Officer and principal executive officer, effective the same date.
Under an interim employment agreement, Mr. Civik will receive an annualized base salary of $710,000 and be eligible for a target bonus equal to 60% of that salary, prorated for his service. Subject to Board approval, he will receive stock options for 1.1% of outstanding common stock vesting in 12 equal monthly installments during his interim term, and an additional fully vested option for 0.4% of outstanding common stock upon completion of a successful financing or strategic transaction during the interim term or within six months after.
A concurrent press release highlights the Board’s ongoing search for a permanent CEO and emphasizes continuity for Pyxis Oncology’s lead antibody-drug conjugate, micvotabart pelidotin (MICVO), which is being evaluated in Phase 1 and Phase 1/2 clinical studies in recurrent/metastatic head and neck squamous cell carcinoma and other solid tumors.
Pyxis Oncology, Inc. reported that Interim Chief Executive Officer and director Thomas Civik received a new stock option grant. On February 3, 2026, he was awarded an option to purchase 690,131 shares of common stock at an exercise price of $1.49 per share, expiring on February 3, 2036.
The option vests in 12 equal monthly installments, starting on the grant date, and each monthly vesting is conditioned on his continued service as Interim Chief Executive Officer through the applicable vesting date. Following this grant, he beneficially owns 690,131 derivative securities directly in the form of this option.
Pyxis Oncology, Inc. reported positive preliminary Phase 1 data for its antibody-drug conjugate micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma. In the monotherapy cohort at 5.4 mg/kg, 18 patients were treated and 13 were evaluable, showing a confirmed overall response rate of 46% (6/13), including one complete response, and a disease control rate of 92% (12/13). MICVO was generally well tolerated, with no Grade 4 ADC payload treatment-related adverse events of interest or Grade 5 events, though Grade ≥3 treatment-related events occurred in 56% of patients and 28% discontinued treatment.
In combination with KEYTRUDA, 7 patients were treated, all evaluable, with a confirmed overall response rate of 71% (5/7) and a disease control rate of 100% (7/7), and no Grade 3 or 4 ADC payload treatment-related events of interest or treatment-related discontinuations reported. The company also completed the sale of its rights to royalties from the commercialization of Enzeshu for a one-time cash payment of
Pyxis Oncology, Inc. has filed a shelf registration statement allowing it to offer up to $350,000,000 of securities, including common stock, preferred stock, debt, warrants, rights and units, over time. The specific terms and prices of each issuance will be set in future prospectus supplements.
Within this shelf, Pyxis also established an at-the-market program under which it may sell up to $150,000,000 of common stock from time to time through Leerink Partners, which will act as sales agent and receive up to 3.0% of the gross proceeds. Net proceeds from any sales are expected to be used for general corporate purposes such as working capital, operating expenses and capital expenditures, and potentially for complementary acquisitions.
Pyxis is a clinical-stage oncology company focused on solid tumors, particularly head and neck squamous cell carcinoma, and remains an emerging growth and smaller reporting company, which permits reduced public reporting requirements.
Pyxis Oncology (PYXS) reported Q3 2025 results, highlighting ongoing R&D investment and a going concern warning. The company posted a net loss of $22.0 million for the quarter on zero revenue. Operating expenses were $23.5 million, including $17.8 million in research and development and $5.7 million in general and administrative costs.
As of September 30, 2025, Pyxis held $76.3 million in cash, cash equivalents, and short‑term investments, with total assets of $105.6 million and stockholders’ equity of $68.8 million. Net cash used in operating activities was $53.1 million for the nine months ended September 30, 2025. The company disclosed that current liquidity will not be sufficient to fund operations over the next 12 months, which raises substantial doubt about its ability to continue as a going concern.
Pipeline updates center on micvotabart pelidotin (MICVO). The FDA granted Fast Track Designation in February 2025 for recurrent/metastatic HNSCC monotherapy after platinum and anti‑PD-(L)1 therapy. Pyxis recognized $2.8 million in milestone revenue in the nine‑month period tied to Suvemcitug approval in China. Common shares outstanding were 62,264,215 as of October 31, 2025.
Pyxis Oncology (PYXS) furnished a Form 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The press release is provided as Exhibit 99.1.
The company indicated the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
GordonMD entities and Craig D. Gordon report a passive 13G stake in Pyxis Oncology (PYXS). The filing shows that GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon each report shared voting and dispositive power over 3,834,740 shares of Pyxis common stock, representing 6.2% of the class. All reported securities are owned by advisory clients of GordonMD Global Investments LP, with GordonMD Long Biased Master Fund LP identified as one advisory client that may hold more than 5%. The filing certifies the position is not intended to change or influence control of the issuer and includes a joint filing agreement and a control-person identification exhibit.
Pyxis Oncology (PYXS) is a clinical-stage oncology company focused on micvotabart pelidotin and reports significant historical losses with the expectation of continued losses while it advances development. The company has 62,018,135 shares outstanding as of June 30, 2025 and 190,000,000 shares authorized. It states a need for substantial additional capital and that failure to raise funds could delay or cut research, development or commercialization efforts. Preclinical and early clinical signals for micvotabart pelidotin are highlighted: robust tumor growth inhibition across patient-derived xenograft models, complete responses in multiple indications, tolerability in animal studies, and enhanced efficacy in combination with anti-PD-1. The company plans two ~20-patient expansion cohorts at 5.4 mg/kg IV Q3W with preliminary data expected in the second half of 2025 and the first half of 2026. Material business risks include regulatory, manufacturing, intellectual property and third-party reliance, and the company recorded no federal income tax provision for recent periods.
Pyxis Oncology, Inc. furnished an update on its business by issuing a press release with its financial results for the quarter ended June 30, 2025 and a broader corporate update. The company submitted this information in a current report so investors can access the press release, which is attached as Exhibit 99.1. The report clarifies that the press release and related information are being furnished, not filed, which limits certain legal liabilities and means the material is not automatically incorporated into other regulatory documents.